Hen Suh Park

Director at Oncosynergy.

Raised on Oncosynergy filings

$6.6M

of $8.2M offered across 1 Form D filing

Company

Biotech · Stamford, CT

Beta-1 integrin antibody for recurrent glioblastoma

Beta-1 integrin antibody for recurrent glioblastoma

Oncosynergy Form D filings
Filed	Security	Sold of offered	Filing
May 26, 2026	Equity	$6.6M/ $8.2M	Form D

Also named on Oncosynergy filings